A DNA aptamer with high affinity and specificity for therapeutic anthracyclines

Analytical Biochemistry

Volumn 373, Issue 1, 2008, Pages 34-42

  Wochner, Aniela ^a,b   Menger, Marcus ^a   Orgel, Dagmar ^a   Cech, Birgit ^a   Rimmele, Martina ^a   Erdmann, Volker A ^b   Glökler, Jörn ^a  

^a RiNA Netzwerk RNA Technologien   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Competition assay; Daunomycin; DNA aptamer; Doxorubicin; In vitro selection; SELEX

Indexed keywords

BINDING ENERGY; CHEMOTHERAPY; DISSOCIATION;

COMPETITION ASSAYS; DAUNOMYCIN; DNA APTAMER; DOXORUBICIN; IN-VITRO; SELEX;

DNA;

ANTHRACYCLINE DERIVATIVE; APTAMER; DAUNORUBICIN; DNA; DOXORUBICIN;

ARTICLE; AUTOMATION; BIOTINYLATION; DISSOCIATION CONSTANT; DNA BINDING; DNA DETERMINATION; DRUG DNA BINDING; GENE TARGETING; NUCLEOTIDE SEQUENCE; PH; PRIORITY JOURNAL;

EID: 37049008251     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.09.007     Document Type: Article

References (53)

1. Zagotto G., Gatto B., Moro S., Sissi C., and Palumbo M. Anthracyclines: Recent developments in their separation and quantitation. J. Chromatogr. B 764 (2001) 161-171
2. Blum R.H., and Carter S.K. Adriamyc: A new anticancer drug with significant clinical activity. Ann. Intern. Med. 80 (1974) 249-259
3. Calendi E., Dimarco A., Reggiani M., Scarpinato B., and Valentini L. On physico-chemical interactions between daunomycin and nucleic acids. Biochim. Biophys. Acta 103 (1965) 25-49
4. Huffman D.H., and Bachur N.R. Daunorubicin metabolism in acute myelocytic leukaemia. Blood 39 (1972) 637-643
5. Alberts D.S., Bachur N.R., and Holtzman J.L. The pharmacokinetics of daunomycin in man. Clin. Pharmacol. Ther. 12 (1971) 96-104
6. Mahnik S.N., Lenz K., Weissenbacher N., Mader R.M., and Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bioreactor system. Chemosphere 66 (2007) 30-37
7. Speth P.A., Raijmakers R.A., Boezeman J.B., Linssen P.C., de Witte T.J., Wessels H.M., and Haanen C. In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells. Eur. J. Cancer Clin. Oncol. 24 (1988) 667-674
8. Alexy R. Antibiotics in the aquatic environment: input, elimination, and impact on bacteria. Faculty for Chemistry, Pharmacy, and Geosciences (2003), Albert-Ludwigs-University, Freiburg
9. Sastry C.S.P., and Rao J.S.V.M.L. Determination of doxorubicin hydrochloride by visible spectrophotometry. Talanta 43 (1996) 1827-1835
10. Fogli S., Danesi R., Innocenti F., Di Paolo A., Bocci G., Barbara C., and Del Tacca M. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther. Drug Monit. 21 (1999) 367-375
11. Lachatre F., Marquet P., Ragot S., Gaulier J.M., Cardot P., and Dupuy J.L. Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B 738 (2000) 281-291
12. van Asperen J., van Tellingen O., and Beijnen J.H. Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J. Chromatogr. B 712 (1998) 129-143
13. Perez-Ruiz T., Martinez-Lozano C., Sanz A., and Bravo E. Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis 22 (2001) 134-138
14. Simeon N., Chatelut E., Canal P., Nertz M., and Couderc F. Anthracycline analysis by capillary electrophoresis: Application to the analysis of daunorubicin in Kaposi sarcoma tumor. J. Chromatogr. A 853 (1999) 449-454
15. Reinhoud N.J., Tjaden U.R., Irth H., and van der Greef J. Bioanalysis of some anthracyclines in human plasma by capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. 574 (1992) 327-334
16. Ellington A.D., and Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990) 818-822
17. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
18. Rimmele M. Nucleic acid aptamers as tools and drugs: Recent developments. ChemBioChem 4 (2003) 963-971
19. 2+. RNA 1 (1995) 538-550
20. Lorsch J.R., and Szostak J.W. In vitro selection of RNA aptamers specific for cyanocobalamin. Biochemistry 33 (1994) 973-982
21. Wilson D.S., and Szostak J.W. In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 68 (1999) 611-647
22. Bock L.C., Griffin L.C., Latham J.A., Vermaas E.H., and Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355 (1992) 564-566
23. Weiss S., Proske D., Neumann M., Groschup M.H., Kretzschmar H.A., Famulok M., and Winnacker E.L. RNA aptamers specifically interact with the prion protein PrP. J. Virol. 71 (1997) 8790-8797
24. + cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94 (1999) 368-371
25. S. A. Doyle, M. B. Murphy, Aptamers and methods for their in vitro selection and uses thereof, U.S. patent 20050142582 (2005).
26. Bacher J.M., and Ellington A.D. Nucleic acid selection as a tool for drug discovery. Drug Disc. Today 3 (1998) 265-272
27. Famulok M. Allosteric aptamers and aptazymes as probes for screening approaches. Curr. Opin. Mol. Ther. 7 (2005) 137-143
28. Cunningham Jr. E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., Goldbaum M., Guyer D.R., Katz B., Patel M., and Schwartz S.D. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
29. Siddiqui M.A., and Keating G.M. Pegaptanib: In exudative age-related macular degeneration. Drugs 65 (2005) 1571-1577
30. Menger M., Glokler J., and Rimmele M. Application of aptamers in therapeutics and for small-molecule detection. In: Erdmann V.A., Brosius J., and Barciszewski J. (Eds). RNA towards Medicine (2006), Springer, Berlin 359-373
31. M. Rimmele, D. Orgel, Use of an analysing substance for detecting an explosive, patent WO 2004024948-A (2004).
32. Liu J., Mazumdar D., and Lu Y. A simple and sensitive "dipstick" test in serum based on lateral flow separation of aptamer-linked nanostructures. Angew. Chem. Intl. Ed. 45 (2006) 7955-7959
33. Drolet D.W., Moon-McDermott L., and Romig T.S. An enzyme-linked oligonucleotide assay. Nat. Biotechnol. 14 (1996) 1021-1025
34. Wochner A., Cech B., Menger M., Erdmann V.A., and Glökler J. Semi-automated selection of DNA aptamers using magnetic particle handling. BioTechniques 43 (2007) 344-353
35. Sugawara K., Hirabayashi G., Kamiya N., Kuramitz H., and Tanaka S. Evaluation of binding between electroactive biotin derivative and streptavidin immobilized on chitin film. Electroanalysis 17 (2005) 1659-1664
36. Wochner A., and Glokler J. Nonradioactive fluorescence microtiter plate assay monitoring aptamer selections. BioTechniques 42 (2007) 578-582
37. Stoltenburg R., Reinemann C., and Strehlitz B. FluMag-SELEX as an advantageous method for DNA aptamer selection. Anal. Bioanal. Chem. 383 (2005) 83-91
38. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415
39. Santa Lucia Jr. J. A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc. Natl. Acad. Sci. USA 95 (1998) 1460-1465
40. Davis J.T. G-quartets 40 years later: From 5′-GMP to molecular biology and supramolecular chemistry. Angew. Chem. Intl, Ed. 43 (2004) 668-698
41. Huppert J.L., and Balasubramanian S. Prevalence of quadruplexes in the human genome. Nucleic Acids Res. 33 (2005) 2908-2916
42. Huppert J.L., and Balasubramanian S. G-quadruplexes in promoters throughout the human genome. Nucleic Acids Res. 35 (2007) 406-413
43. Saito T., and Tomida M. Generation of inhibitory DNA aptamers against human hepatocyte growth factor. DNA Cell Biol. 24 (2005) 624-633
44. Cheng G.-F., Zhao J., Tu Y.-H., He P.-G., and Fang Y.-Z. Study on the interaction between antitumor drug daunomycin and DNA. Chin. J. Chem. 23 (2005) 576-580
45. Nutiu R., and Li Y. Structure-switching signaling aptamers: Transducing molecular recognition into fluorescence signalling. Chemistry 10 (2004) 1868-1876
46. Baldrich E., Restrepo A., and O'Sullivan C.K. Aptasensor development: Elucidation of critical parameters for optimal aptamer performance. Anal. Chem. 76 (2004) 7053-7063
47. Potyrailo R.A., Conrad R.C., Ellington A.D., and Hieftje G.M. Adapting selected nucleic acid ligands (aptamers) to biosensors. Anal. Chem. 70 (1998) 3419-3425
48. Lee M., and Walt D.R. A fiber-optic microarray biosensor using aptamers as receptors. Anal. Biochem. 282 (2000) 142-146
49. Porstmann B., Porstmann T., and Nugel E. Comparison of chromogens for the determination of horseradish peroxidase as a marker in enzyme immunoassay. J. Clin. Chem. Clin. Biochem. 19 (1981) 435-439
50. Gallati H. Horseradish peroxidase: A study of the kinetics and the determination of optimal reaction conditions, using hydrogen peroxide and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) as substrates. author's traslation of original title. J. Clin. Chem. Clin. Biochem. 17 (1979) 1-7
51. Arts M.J., Haenen G.R., Voss H.P., and Bast A. Antioxidant capacity of reaction products limits the applicability of the Trolox equivalent antioxidant capacity (TEAC) assay. Food Chem. Toxicol. 42 (2004) 45-49
52. Fujiwara K., Shin M., Hougaard D.M., and Larsson L.I. Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies. Histochem. Cell. Biol. 127 (2007) 69-77
53. Smith C.K., Davies G.J., Dodson E.J., and Moore M.H. DNA-nogalamycin interactions: The crystal structure of d(TGATCA) complexed with nogalamycin. Biochemistry 34 (1995) 415-425